of surgical procedure, duration of anesthesia, and surgery are few of the important determinants for risk of PONV. PONV can lead to delay in recovery, wound dehiscence, and prolonged hospitalization. Its prevalence has been reported in different studies about 44%-83%. [2, 3] The incidence following LC is as high as 46%-72%. [4, 5] The etiology of PONV is not still clear, but it is probably a multifactorial phenomenon. [6, 7] During laparoscopy, gas entrance into the abdominal cavity can cause increased pressure of peritoneal cavity which may lead to PONV. [8] Prolonged CO 2 pneumoperitoneum can lead to peritoneal distention and diaphragmatic stimulation. It leads to stretching of mechanoreceptors, increased serotonin (5-hydroxytryptamine ) synthesis and PONV. Intra-abdominal manipulation is one of the causes of PONV. [6, 7] One of the first-line therapeutic agents for the prevention of PONV is serotonin 5-HT type 3 (5-HT 3 ) receptor antagonists. Because of their good efficacy and minimal side effects, 5-HT 3 receptor antagonists are most widely used antiemetic. [8] Palonosetron is the latest entrant in this 5-HT 3 receptor antagonist group. It has a higher receptor-binding affinity and a longer plasma half-life than older 5-HT 3 receptor antagonist such as ondansetron, granisetron, dolasetron, and ramosetron. Palonosetron shows allosteric binding and positive cooperativity which triggers receptor internalization. This results into persistent inhibition of 5-HT 3 receptor function and long duration of action. [9] [10] [11] Some studies reported that palonosetron was more effective than ondansetron in preventing chemotherapy-induced nausea and vomiting (CINV) [12] and PONV. [13] Granisetron selectively blocks the 5-HT 3 receptor with a relatively short half-life of 4-9 h. Granisetron is a potent and highly selective 5-HT 3 receptor antagonist that has little or no affinity for other 5-HT receptors or dopaminergic, adrenergic, benzodiazepine, histaminic, or opioid receptors. [14] In contrast, other 5-HT 3 receptor antagonists have affinities for various receptor-binding sites. Although not proven, the binding of these agents to additional receptor subtypes other than their target receptor may underlie the inferior adverse event profile seen with ondansetron compared with granisetron. [15, 16] We hypothesized that long-acting palonosetron treatment would be more effective in lowering the incidence of PONV, compared to treatment with granisetron. The purpose of this study was to prospectively evaluate the efficacy of palonosetron and granisetron in the prevention of PONV in patients undergoing laparoscopic abdominal surgery.
MateRials and Methods
The study proposal was finalized and approved by the institution ethical committee before the investigation was initiated. This study enrolled 80 patients scheduled for elective laparoscopic abdominal surgery under general anesthesia. They ranged in the age group from 20 to 60 years (mean = 46 years). Written informed consent was acquired from all participants before enrollment in the study. This investigator-initiated, prospective, double-blinded, randomized controlled trial was performed at a tertiary care hospital between November 2012 and November 2014. Through a computer-generated randomization schedule, patients were randomly allocated into two groups to receive palonosetron (n = 40) or granisetron (n = 40) [ Figure 1 ].
Exclusion criteria were as follows: allergy to any of the experimental drugs, opioid dependence, a history of PONV and motion sickness, use of antiemetic medication within 24 h before surgery, pregnancy, inability to comprehend the 10 cm visual analog scales (VASs; 0 -none; 10 -maximum) for pain and nausea assessment, and unwillingness to be enrolled in the study. Furthermore, those who had received cancer chemotherapy within 4 weeks or emetogenic radiotherapy within 8 weeks before study entry and patients with ongoing vomiting from gastrointestinal disease were also excluded from the study.
The patients were allocated randomly into two groups with the help of computer-generated random number table. Patients of Group A were given palonosetron 0.075 mg and patients of Group B were given granisetron 2 mg intravenously (IV) along with premedication, immediately before induction of general anesthesia. Normal saline was added to bring the total injectable volume to 2.5 ml in each group. Two theater assistants were used to enroll the patients in groups and to prepare the study drugs. However, both were unaware of the study protocol and were not involved in the study for any further evaluation of patients.
The patients were kept fasting for 8 h and received tablet alprazolam 0.25 mg orally as premedication. Intraoperative monitoring consisted of electrocardiogram, noninvasive blood pressure, and oxygen saturation (SpO 2 ). Baseline vital parameters such as heart rate, blood pressure, and oxygen saturation (SpO 2 ) were recorded. After securing the intravenous line, patients were premedicated with injection rabeprazole 20 mg IV and injection midazolam 1 mg IV. With the help of facemask, preoxygenation with 100% oxygen (O 2 ) was done. After pretreatment with the study drugs, anesthesia was induced with propofol 2 mg/kg body weight and maintained with oxygen and nitrous oxide mixture (50:50). Injection atracurium besylate 0.5 mg/kg body weight was used to facilitate endotracheal intubation. Isoflurane (0.7-1.3 MAC) and injection atracurium besylate 0.1 mg/kg body weight was used as a muscle relaxant. After induction, nasogastric tube was inserted and suction was applied to empty the stomach. Positive pressure ventilation was delivered with tidal volume and respiratory rate adjusted to maintain end-tidal CO 2 between 30 and 40 mm of mercury (mmHg). The intra-abdominal pressure was maintained between 10 and 12 mmHg throughout the surgery with the help of CO 2 . Ropivacaine 0.2% was infiltrated at each surgical port before skin closure for postoperative analgesia. In addition, injection, tramadol HCl 2 mg/kg body weight and injection paracetamol 20 mg/kg body weight was administered IV for intraoperative analgesia. During surgery, ringer lactate was infused in accordance with maintenance of volume requirements. Glycopyrrolate 10 mg/kg IV and neostigmine 50 mg/kg were used for reversal of residual neuromuscular blockade. The nasogastric tube was suctioned again and then removed before tracheal extubation. The total duration of CO 2 insufflation, duration of surgery, and the total volume of fluid administered during surgery were recorded.
Postoperatively, all patients were observed by dedicated resident doctors who were unaware of the study drug. Nausea was defined as a subjectively unpleasant sensation associated with the urge to vomit. Incidences of vomiting included retching (defined as the labored, spastic, rhythmic contraction of the respiratory muscles without expulsion of the gastric contents) and actual vomiting (defined as the forceful expulsion of gastric contents from the mouth). A complete response to palonosetron and granisetron was defined as an absence of PONV and no need for further rescue antiemetic drugs. All data were collected for 0-2 h in postanesthesia care unit and from 2 to 48 h in postoperative ward. All patients were observed postoperatively for 48 h (divided into intervals, i.e. 0-2, 2-6, 6-24, and 24-48 h) for number of episodes of nausea, retching, and vomiting and side effects of the study drugs. Time to the first rescue antiemetic (metoclopramide 10 mg IV) was also noted in each group. Nausea was assessed using VAS (0-10, 0 = no nausea and 10 = worst possible nausea). A score of >5 was considered severe, 5 = moderate, and <5= mild nausea. The vomiting episodes of >2 were considered as severe, 2 as moderate, and <2 as mild. Rescue antiemetic metoclopramide 10 mg IV was given for moderate and severe nausea or vomiting episode. Patients were monitored for postoperative pain by VAS (0-10, 0 = no pain and 10 = worst imaginable pain), and diclofenac 1.5 mg/kg IV was given on demand or when VAS was found 4 or more. In case of persistent pain for >30 min after diclofenac administration, injection tramadol 50 mg IV was planned as second rescue analgesic. Figure 2 ]. This prospective was conducted on eighty patients undergoing elective laparoscopic surgeries which included cholecystectomy, appendectomy, hernioplasty, mesh repair, splenectomy, common bile duct exploration, totally extraperitoneal repair, and diagnostic laparoscopy (gynecological laparoscopic surgeries were not included in the study).
On the basis of the ASA physical status classification, the distribution of patients in both groups is shown in periods, the hemodynamic data were noted at regular intervals. There was no statistically significant difference in the measurement of vitals of the two groups.
The distribution of both groups on the basis of occurrence of nausea, vomiting, overall PONV, and rescue antiemetic administration is displayed in Table 3 and Figure 4 . The overall PONV at 0-2 h was high (27.5%) in Group B as compared to Group A (15%). However, the difference was not statistically significant (P = 0.17). Furthermore, in both the groups, no rescue antiemetic was used.
At 2-6 h, the comparison of both groups is presented in Table 3 and Figure 4 . In Group A, 7 out of 40 (17.5%) had overall PONV while the same in Group B was 13 out of 40 (32.5%). As is clear, the incidence of PONV was higher in Group B, but it was not statistically significant (P = 0.12). The requirement of antiemetic was same in both groups (n = 2).
At 6-24 h [ Table 3 and Figure 4 ], 8 out of 40 (20%) in Group A and 12 out of 40 (30%) in Group B experienced overall PONV postoperatively. However, the difference is not statistically significant (P = 0.0.3). Similarly, in Group A, the requirement of rescue antiemetic at 6-24 h postoperatively was nil while the same in Group B was 10% (n = 4).
At 24-48 h, postoperatively, incidence of PONV is more in the patients of Group B, n = 15 (37.5%) as compared to Group A, n = 7 (17.5%) at 24-48 h [ Table 3 and Figure 4 ]. The difference between the groups is statistically highly significant (P = 0.04). However, the number of patients requiring the rescue antiemetic was statistically not significant in both the groups.
Overall, significantly, a greater number of participants suffered PONV in the later (24-48 h) postoperative period if they were in the granisetron group compared with the palonosetron group. However, this difference between the groups was statistically insignificant in the early (0-24 h) postoperative period. The incidence of PONV in granisetron group was found to be maximum in the 24-48 h period, n = 15 (37.5). The incidence of PONV in palonosetron group was found to be maximum in 12-48 h period but in lesser number of patients, n = 8 (20%). In addition, the PONV score was less in the palonosetron group, implying that these patients had fewer episodes of PONV. Furthermore, the overall requirement of rescue antiemetic [ Table 3 and Figure 4 ] was higher (n = 9) in granisetron group as compared to palonosetron group (n = 6). This requirement was higher in early postoperative period as compared to late postoperative period. However, the difference was small and comparable.
The incidence of most of the common side effects, such as headache, dizziness, drowsiness, and constipation [ Table 4 and Figure 5 ], is similar in both the groups. As shown, the incidence of adverse effects is not clinically serious or significant. All the events are of mild-to-moderate severity and settle spontaneously without separate treatment.
discussion
In modern anesthetic practice, PONV remains a significant problem. Depending on the various risk factors such as duration of surgery, the type of anesthetic agent used, and smoking habit, postoperative period is associated with variable incidence of nausea and vomiting. [17] PONV is associated with various adverse consequences such as delayed recovery, unexpected hospital admission, pulmonary aspiration, and [18] Therefore, in surgical patients, the prevention of PONV gets similar priority to that of alleviating postoperative pain. [19] The primary event in the initiation of vomiting reflex is the stimulation of 5-HT 3 receptors. In periphery, these receptors are situated on the nerve terminal of vagus nerve and centrally on the chemoreceptor trigger zone (CTZ) of the area postrema. [20] The etiology of PONV is very complex in nature. The triggering factors are multiple inputs arriving from multiple areas. Anesthetic agents initiate the vomiting reflex by stimulating the central 5-HT 3 receptors on CTZ. [18, [21] [22] [23] Laparoscopic surgery, female gender, and nonsmoker status are considered as important independent risk factors for PONV. [24] The reported incidence of PONV is 30%-80% within the first 24 h after laparoscopic surgery when no prophylactic antiemetic is administered. [7, 25, 26] The exact mechanism of PONV caused by pneumoperitoneum is not known. Pneumoperitoneum increases the risk of PONV by probably stimulating the mechanoreceptors in the gut. Furthermore, the intestinal ischemia induced by it may release serotonin and other neurotransmitters, which could lead to PONV. [27] Acetylcholine and histamine are two important neurotransmitters of the vomiting center. Dopamine and 5-HT are two important neurotransmitters located in CTZ. 5-HT 3 receptor is a subtype of serotonin receptor found in terminals of the vagus nerve and in certain areas of the brain. 5-HT 3 receptor antagonists (granisetron and palonosetron) are highly specific and selective for acting against nausea and vomiting. They bind to the serotonin 5-HT 3 receptor in CTZ Headache, n (%) 3 (7.5) 1 (2.5) 0.6 Constipation, n (%) 3 (7.5) 4 (10) 0.9 Drowsiness, n (%) 1 (2.5) 1 (2.5) 1 24-48 h Headache, n (%) 0 2 (5) 0.4 Constipation, n (%) 0 0 *N/A Drowsiness, n (%) 0 0 *N/A *N/A; not applicable due to small number of samples and at vagal efferent in the gastrointestinal tract. [12, 28] Based on the studies of Candiotti et al., the food drug agency has approved an effective dose of 0.075 mg for palonosetron. In our study, we also used palonosetron as 0.075 mg. With a single dose, palonosetron is effective in preventing nausea and vomiting for a longer period of time. This makes it more cost-effective. Granisetron produces irreversible block of the 5-HT 3 receptors. This may account for the longer duration of this drug. [29, 30] For the treatment of CINV, the effective dose of granisetron is 40-80 µg/kg). In this study, 2.5 mg was selected as dose of granisetron. This is within its effective dose range (40-80 µg/kg. The current study was planned in accordance with the studies conducted by Tramèr et al. [25] and del Giglio et al. [31] In this study, all surgical and anesthetic factors were well controlled. As a result, any difference in emesis-free episodes is directly attributed to the study drugs.
Our study suggests that palonosetron has an antiemetic effect which lasts longer than granisetron. The exact reason for the difference in effectiveness between palonosetron and granisetron is not known. In the present study, all the two antiemetics were shown to be almost equally effective in preventing nausea and vomiting during the first 24 h (0-24 h) after laparoscopic surgery. During first 24 h, there were no statistically significant differences in the number of PONV events between the two groups. The present study reports an overall PONV incidence of 20%-33% within the first 24-h postsurgery, without any statistical difference between the two groups. Our study demonstrates that the efficacy of palonosetron for the prevention of PONV is similar to that of granisetron during the early postoperative period (0-24 h). However, palonosetron appears to have a longer duration of action and its effect lasts for >24 h after the surgery. As a result, the palonosetron is more effective than granisetron for getting a complete response (no PONV and no rescue medication) for 24-48 h. The probable reason for the differences in effectiveness between granisetron and palonosetron could be related to the binding affinities of 5-HT 3 receptor antagonist and/or to the half-lives (palonosetron 40 h vs. granisetron 8-9 h). [10, 12] In our study, a control group receiving placebo was not included. Aspinall and Goodman suggested that if active drugs are available, placebo-controlled trials may be unethical because PONV is very much disturbing and distressing event that can occur after laparoscopic surgery.
Our results are comparable with the study performed by Bhattacharjee et al. [32] [ Table 5 ]. They did a comparative study between palonosetron and granisetron to prevent PONV after LC. They also concluded that prophylactic therapy with palonosetron is more effective than granisetron for the long-term prevention of PONV after laparoscopic surgery. Similar to our study, the incidence of PONV was maximum in the 24-48 h period with 43.3% of patients experiencing PONV in Group B and 16.6% in Group A while PONV incidence in our study was 37.5% in Group B and 17.5% in Group A in the 24-48 h period. This implied that the maximum incidence of PONV was observed in late postoperative period.
Gugale and Bhalerao [33] conducted a study using granisetron 0.05 mg/kg and palonosetron 1.5 µg/kg in patients undergoing elective laparoscopic surgery under general anesthesia. In this study, all patients were observed postoperatively for 72 h divided into intervals, i.e. 0-4, 4-8, 8-12, 12-24, and 24-72 h. If we consider the 4-24 h period, the overall incidence of PONV in their study was 19.8% in Group B and 16.6% in Group A. This incidence is similar to our findings of 20% in Group A and 30% in Group B at 6-24 h postoperative period. Gugale and Bhalerao also concluded that the incidence of PONV was maximum in later postoperative period. At 24-48 h period, they noted 43.3% of patients experiencing PONV in Group B and 16.6% in Group A at 24-48 h period, and our values are 37.5% in Group B and 17.5% in Group A.
Similarly, according to Candiotti et al., [34] incidence of PONV was 26% between 0 and 24 h and 51% in 24-48 h in patients who received 0.075 mg palonosetron before induction as compared to 57% and 59%, respectively, in patients who received placebo. This value is higher than that observed in our study. In the study conducted by Kovac et al., [35] incidence of PONV was 44% in patients receiving palonosetron 0.075 mg in 0-24 h and 30% in 24-48 h. This value is again higher than that was observed by us. The variation in the observations may be due to surgical technique, intraoperative use of different anesthetic drugs, suctioning at the time of extubation, postural changes, and residual pneumoperitoneum.
Headache, drowsiness, dizziness, and constipation are the adverse events that are most frequently reported while using 5-HT 3 receptor antagonists. [36] The adverse events observed in our study were similar among all two groups of patients.
conclusion
Our study demonstrated that palonosetron and granisetron are almost equally effective as antiemetic against PONV during early postoperative period (0-24 h). During this period, the incidence of PONV is higher with granisetron, but the difference is statistically insignificant. However, prophylactic therapy for the long-term (24-48 h) prevention of PONV after laparoscopic surgery palonosetron is more effective than granisetron.
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